Home
overview
It is an unfortunate reality that many of the ischeamic injury drugs available have been beset with major problems and have failed during clinical trials. The significant gap in efficacious treatments clearly highlights the need for innovative new therapies to help limit the disability and devastation caused by this debilitating disease.

This essential conference will involve senior industry figures that will address the development and latest advancements in therapeutics designed to target key molecular pathways dysregulated during ischaemic cellular injury. Novel opportunites for ischaemia treatments will include therapeutic neuroprotectants, anti-inflammatories, thrombolytics and anti-oxidants. From novel compounds at preclinical stages to successful existing therapeutics this conference will be both informative and focussed.

Ischaemic Injury: Novel Targets and Therapeutics is organised and produced by SMi: we specialise in providing senior executives with timely, strategic and focused up to date information. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry and government figures and seek their advice and opinions.

Please register now to guarantee your place at this essential conference.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Ronald Mervis

Dr Ronald Mervis, President & Chief Scientific Officer, Neuro-Cognitive Research

9:10 CURRENT PATIENT PATHWAYS THROUGH THE MEDICAL SYSTEM

Helen Smith

Helen Smith, Head, Cardiovascular Services, Datamonitor Healthcare

  • Acute medical and surgical treatment received; Post stroke prevention and rehabilitation; Patient outcomes
  • Cost containment issues in treatment; Impact of stroke awareness campaigns on early detection and treatment; Identification of unmet needs
  • Awareness of and attitudes to R&D products in development for ischaemic stroke
  • Neuroprotective agents; Thrombolytics; GPIIb/IIIa inhibitors
  • Low molecular weight heparins
  • Emerging technologies and surgical procedures
  • 9:40 THERAPEUTIC INTERVENTIONS AND NEUROIMAGING

    Dr Geoffrey Dunbar

    Dr Geoffrey Dunbar, Vice President, Neuroscience Clinical R&D, Bristol Myers Squibb

  • Preventive therapies
  • Co-ordinated stroke management: need for speed + cocktail approach
  • Use of sophisticated neuroimaging
  • Case study MaxiPost: a first in class neuroprotectant
  • 10:20 FROM ANIMAL MODELS TO PROOF OF PRINCIPLE TRIALS

    Dr James Vornov

    Dr James Vornov, Associate Director, Clinical Research, Guilford Pharmaceuticals

  • What does predictability mean?
  • How do areas of uncertainty in stroke drug development affect lead compound selection?
  • How can pharmacokinetics and pharmacodynamics be used to improve predictions?
  • Can clinical trial simulations help in moving from biomarkers to predicting clinical effect?
  • 11:00 Morning Coffee

    11:20 IMMORTALISED BRAIN STEM CELL TRANSPLANTATION FOR STROKE THERAPEUTICS: 21ST CENTURY CELLS

    Dr Martin Edwards

    Dr Martin Edwards, Chief Executive Officer, ReNeuron Pharmaceuticals

  • Development of pluripotent immortalised human neural cell lines
  • Neuroregeneration by replenishing damaged circuits
  • Preclinical data
  • Regulatory issues
  • Potential impact of human cell-based products in ischaemic stroke management
  • 12:00 TARGETING SODIUM CHANNELS IN ISCHAEMIA PATIENTS

    Dr Terry Smith

    Dr Terry Smith, Group Development Director, CeNeS

  • Sodium channels: key sites for neuroprotection
  • Development of Sipatrigine
  • Mechanism of action of Sipatrigine
  • Clinical trial safety data
  • Clinical trial design using MRI techniques for surrogate markers
  • 12:40 Networking Lunch

    14:00 TARGETING INTRACELLULAR BIVALENT IONS

    Dr Itzchak Angel

    Dr Itzchak Angel, Vice President, R&D, D-Pharm

  • Role of bivalent ions in the ischaemic cascade and in neurodegeneration
  • Approaches for regulating bivalent ions levels and functions
  • Membrane activated chelators (Macs): effective drug targets for ischaemia
  • Update on the effects of DP-b99 in ischaemic models
  • Results from clinical studies
  • 14:40 NEOTROFIN: MODULATION OF NEUROTROPHIC FACTORS AND THE TREATMENT OF STROKE

    Eve Taylor

    Eve Taylor, Head, Physiology & Pharmacology, Neotherapeutics

  • Neotrofin and the release of neurotrophic factors
  • Prevention of cell death by Neotrofin
  • Neuroregeneration and its role in recovery from stroke
  • Neotrofin and neuroregeneration
  • 15:20 Afternoon Tea

    15:40 EBSELEN DEVELOPMENT IN ACUTE STROKE

    Dr Hiroyuki Masayasu

    Dr Hiroyuki Masayasu, Associate General Manager, Daiichi

  • Characteristics of Ebselen as an anti-oxidant
  • Pre-clinical evaluation in ischaemic models
  • Clinical development of Ebselen: pronounced anti-ischaemic effects
  • Forecast
  • 16:00 PROTECTING ISCHAEMIC MYOCARDIUM

    Prof Michael Marber

    Prof Michael Marber, Professor of Cardiology, Kings College London, Guys and St. Thomas’ Hospitals

  • Concept of ischaemic preconditioning
  • Clinical correlate of ischaemic preconditioning
  • Models of preconditioning in patients
  • Signals and targets underlying preconditioning
  • 16:30 UTILISING PROTEOMICS IN ISCHAEMIA R&D

    Dr Alison Pearce

    Dr Alison Pearce, Business Development Manager, Proteome Sciences

  • What is proteomics?
  • Is this a robust identification tool?
  • Applying proteomics to ischaemia research
  • Research directions at Proteome
  • Successes to date
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Networking Drinks Reception

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Wynne Weston-Davies

    Dr Wynne Weston-Davies, Development Director, Evolutec

    9:10 TARGETING INFLAMMATORY MEDIATORS: OPPORTUNITIES FOR NOVEL THERAPIES

    Dr Andrew Parsons

    Dr Andrew Parsons, Associate Director, SmithKline Beecham

  • The inflammatory reaction: a key pharmacologic opportunity for stroke therapeutics
  • Destructive and protective processes associated with inflammatory mediators
  • The selection process: what molecules should be targeted?
  • The MAPK signalling cascade and cytokine inhibition
  • Future developments: exploiting this fertile ground of opportunity for ischaemic therapies
  • 9:40 INFLAMMATION AND STROKE

    Dr Giora Feuerstein

    Dr Giora Feuerstein, Senior Director, Cardiovascular Diseases Research, Dupont Pharma

  • The significance of inflammation in stroke
  • Positive and negative inflammatory factors in neuroprotection
  • Potential medical benefits of anti-inflammatory agents in stroke
  • 10:20 ADJUNCTIVE THERAPY IN STROKE

    Dr Barbara Araneo

    Dr Barbara Araneo, Vice President, Research, Pharmadigm

  • CNS response to ischaemia
  • DHEA antagonises acute inflammatory responses
  • DHEA antagonises the effects of ischaemic injury
  • DHEA anti-inflammatory action on cell signalling
  • DHEA modulation of inflammatory responses through altered gene expression
  • 11:00 Morning Coffee

    11:20 ANTI-COMPLEMENT THERAPY: A NEW APPROACH TO STROKE MANAGEMENT

    Dr Henry Marsh Jr

    Dr Henry Marsh Jr, Vice President, Research, AVANT Immunotherapeutics

  • Why target the complement system?
  • TP10 and TP20 - multi-functional complement inhibitors
  • Preclinical and clinical studies of TP10 target ischaemic injury
  • TP20 - a combined complement inhibitor and selectin antagonist - targets cerebral stroke
  • The AVANT pipeline
  • 12:00 THROMBOLYTICS FOR INTRAVENTRICULAR HAEMORRHAGE

    Prof Dan Hanley

    Prof Dan Hanley, Jeffrey and Harriet Legum Professor of Acute Care Neurology, John Hopkins Medical Institutions/National Stroke Association

  • Concept of treatment for ICH
  • Animal model
  • Preliminary efficacy in humans
  • FDA orphan drug trial of rt-PA for IVH
  • Surrogate markers for efficacy
  • 12:40 Networking Lunch

    14:00 A NOVEL NEUROPROTECTIVE COMPOUND NEU2000

    Byoung Joo Gwag

    Byoung Joo Gwag, Assistant Professor and director Center for the Interventional Therapy of Stroke & Alzheimer’s Disease Department of Pharmacology, Ajou University School of Medicine

  • Synthesizing a novel neuroprotective compound NEU2000; Prevention of NMDA neurotoxicity at doses of 30 - 1000 mM
  • Neuroprotective action attributed to inhibition of NMDA receptor-mediated Ca2+ influx and current
  • NEU2000 completely blocked free radical neurotoxicity even at 1 mM
  • NEU2000 itself did not produce neuronal injury
  • NEU2000 substantially reduced neuronal death following hypoxic-ischaemic insults in brain and retina
  • Dual and secure neuroprotective action of NEU2000 holds a therapeutic potential to treat hypoxic-ischaemic neuronal death
  • 14:40 MULTI-INTEGRIN RECEPTOR BLOCKADE

    Dr Paul Martin

    Dr Paul Martin, Medical Affairs GB and Ireland, Centocor

  • Basic pharmacology and mechanism of action of GP IIb/IIIa inhibitors
  • Unique properties of abciximab
  • Abciximab in cardiac ischaemia - clinical outcomes and potential mechanisms of action
  • Current studies of abciximab in stroke - medical and interventional therapy
  • Other potential applications of abciximab related to ischaemia and inflammation
  • 15:20 Afternoon Tea

    15:40 CEREBRAL ISCHAEMIC-REPERFUSION INJURY

    Dr Rudolf Urbanics

    Dr Rudolf Urbanics, Deputy R&D Director, Biorex

  • Pathobiological sequela in stroke
  • Rational target identification in a continuously changing event
  • Free radicals in ischaemia-reperfusion
  • The role of HSP-s and NO in stroke
  • 16:20 BRAIN DELIVERY: THE BOTTLE NECK IN CNS TREATMENT

    Prof Anthony Rees

    Prof Anthony Rees, Director of Science, Synt:em

  • The blood brain barrier and today’s drugs
  • Pep:trans - a generic delivery solution for imaging and therapy
  • CNS delivery at work - analgesia and brain cancer
  • An effective solution for delivery of stroke therapeutics
  • Strategies for CNS collaborations
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Imaging Technologies in Ischaemic Drug Discovery and Development
    Workshop

    Imaging Technologies in Ischaemic Drug Discovery and Development

    The Hatton, at etc. venues
    31st January 2001
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.